{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dose+Finding+Study&page=32", "query": { "condition": "Dose Finding Study", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 868, "total_pages": 87, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dose+Finding+Study&page=33&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dose+Finding+Study&page=31&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T03:20:31.058Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00973349", "title": "Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "MF59-eH1N1_f", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2719, "start_date": "2009-09", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2015-12-07", "last_synced_at": "2026-10-25T03:20:31.058Z", "location_count": 20, "location_summary": "Miami, Florida • Lenexa, Kansas • Omaha, Nebraska + 16 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Endwell", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00973349" }, { "nct_id": "NCT04884815", "title": "A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Wilson Disease" ], "interventions": [ { "name": "UX701", "type": "GENETIC" }, { "name": "Standard of Care (SOC)", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "Ultragenyx Pharmaceutical Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2021-09-27", "completion_date": "2034-03", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-25T03:20:31.058Z", "location_count": 12, "location_summary": "Los Angeles, California • Redwood City, California • Sacramento, California + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Redwood City", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04884815" }, { "nct_id": "NCT03152552", "title": "A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus and Heart Failure" ], "interventions": [ { "name": "LIK066", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Empagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2017-07-25", "completion_date": "2018-06-06", "has_results": true, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-10-25T03:20:31.058Z", "location_count": 21, "location_summary": "Huntsville, Alabama • Carmichael, California • Concord, California + 18 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Carmichael", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03152552" }, { "nct_id": "NCT05996835", "title": "Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Kidney Injury Due to Sepsis" ], "interventions": [ { "name": "TIN816 70 mg lyophilisate powder", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 316, "start_date": "2024-01-18", "completion_date": "2026-05-14", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-25T03:20:31.058Z", "location_count": 19, "location_summary": "Birmingham, Alabama • San Francisco, California • Stanford, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Johns Creek", "state": "Georgia" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05996835" }, { "nct_id": "NCT05368285", "title": "A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "barzolvolimab", "type": "BIOLOGICAL" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 208, "start_date": "2022-05-19", "completion_date": "2024-12-20", "has_results": false, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-10-25T03:20:31.058Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Redwood City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05368285" }, { "nct_id": "NCT00738335", "title": "Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "liquid chromatography", "type": "OTHER" }, { "name": "mass spectrometry", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "stereotactic radiosurgery", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2009-01", "completion_date": "2009-07", "has_results": false, "last_update_posted_date": "2012-10-04", "last_synced_at": "2026-10-25T03:20:31.058Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00738335" }, { "nct_id": "NCT02215096", "title": "Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "GSK2636771", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 37, "start_date": "2014-11-13", "completion_date": "2019-10-03", "has_results": true, "last_update_posted_date": "2020-10-22", "last_synced_at": "2026-10-25T03:20:31.058Z", "location_count": 7, "location_summary": "Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02215096" }, { "nct_id": "NCT00231166", "title": "Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "HCD122", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 33, "start_date": "2005-09", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2018-10-11", "last_synced_at": "2026-10-25T03:20:31.058Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Portland, Oregon + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00231166" }, { "nct_id": "NCT03549260", "title": "Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "LDL Cholesterol" ], "interventions": [ { "name": "LIB003", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "LIB Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2018-05-22", "completion_date": "2018-11-30", "has_results": false, "last_update_posted_date": "2019-02-18", "last_synced_at": "2026-10-25T03:20:31.058Z", "location_count": 5, "location_summary": "Indianapolis, Indiana • Louisville, Kentucky • Cincinnati, Ohio", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03549260" }, { "nct_id": "NCT02367196", "title": "A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "CC-90002", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2015-03-12", "completion_date": "2020-12-24", "has_results": false, "last_update_posted_date": "2021-08-12", "last_synced_at": "2026-10-25T03:20:31.058Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • San Francisco, California + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02367196" } ] }